Alterity Therapeutics Ltd. Announces AGM Date

Ticker: PRNAF · Form: 6-K · Filed: Sep 23, 2025 · CIK: 1131343

Alterity Therapeutics Ltd 6-K Filing Summary
FieldDetail
CompanyAlterity Therapeutics Ltd (PRNAF)
Form Type6-K
Filed DateSep 23, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: agm, corporate-governance, filing-update

Related Tickers: ATHE

TL;DR

Alterity Therapeutics (ATHE) set its AGM date, key for shareholder votes.

AI Summary

Alterity Therapeutics Ltd. filed a Form 6-K on September 23, 2025, to report on the date of its Annual General Meeting (AGM) and the closing date for director nominations. This filing is incorporated by reference into several of Alterity's existing Registration Statements on Form S-8 and Form F-3.

Why It Matters

This filing provides crucial dates for shareholders regarding the Annual General Meeting, impacting participation in corporate governance and director elections.

Risk Assessment

Risk Level: low — The filing is routine administrative information about an upcoming shareholder meeting and does not contain new financial or operational risks.

Key Players & Entities

  • Alterity Therapeutics Ltd. (company) — Registrant
  • September 23, 2025 (date) — Filing date and reporting period
  • Form 6-K (document) — Filing type
  • Form S-8 (document) — Incorporated by reference into registration statements
  • Form F-3 (document) — Incorporated by reference into registration statements

FAQ

What is the purpose of this Form 6-K filing?

The Form 6-K is being filed to report the date of Alterity Therapeutics Ltd.'s Annual General Meeting (AGM) and the closing date for director nominations.

When was this Form 6-K filed?

This Form 6-K was filed on September 23, 2025.

Which registration statements is this filing incorporated into?

This Form 6-K is incorporated by reference into Alterity Therapeutics Ltd.'s Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).

What is the principal executive office address of Alterity Therapeutics Limited?

The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia.

Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?

Alterity Therapeutics indicates it files annual reports under Form 20-F.

Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2025-09-23 08:02:41

Filing Documents

From the Filing

OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Date of AGM and Closing Date for Director Nominations 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: September 23, 2025 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.